Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/19214| Title: | Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. | Austin Authors: | Price, Timothy J;Thavaneswaran, Subotheni;Burge, Matthew;Segelov, Eva;Haller, Daniel G;Punt, Cornelis Ja;Arnold, Dirk;Karapetis, Christos S;Tebbutt, Niall C ;Pavlakis, Nick;Gibbs, Peter;Shapiro, Jeremy D | Affiliation: | Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands Cabrini Medical Centre, Monash University, Melbourne, Australia Medical Oncology, Royal North Shore Hospital, Sydney University, Sydney, Australia Medical Oncology, Royal Melbourne and Western Hospitals, Melbourne, Australia Abramson Cancer Centre, University of Pennsylvania, Philadelphia, USA Medical Oncology, The Queen Elizabeth Hospital, Adelaide Colorectal Tumour Group and University of Adelaide, Adelaide, Australia Medical Oncology, Klinik für Tumorbiologie, Freiburg, Germany Medical Oncology, Flinders Medical Centre, Flinders University and Adelaide Colorectal Tumour Group, Adelaide, Australia St Vincent's Clinical School, Faculty of Medicine, University of NSW, Sydney, Australia Medical Oncology, Royal Brisbane Hospital, Brisbane, Australia Medical Oncology, University of Sydney and CTC, Sydney, Australia |
Issue Date: | May-2016 | Publication information: | Expert review of anticancer therapy 2016; 16(5): 557-71 | Abstract: | The treatment of metastatic CRC (mCRC) has evolved over the last 20 years, from fluoropyrimidines alone to combination chemotherapy and new biologic agents. Median overall survival is now over 24 months for RAS mutated (MT) patients and over 30 months for RAS wild-type (WT) patients. However, there are subgroups of patients with BRAF V600E MT CRC who have a significantly poorer outlook. Newer treatment options are also being explored in select subgroups of patients (anti-HER 2 in HER2 positive mCRC and immunotherapy in patients with defective mismatch repair (dMMR)). The best use of these systemic treatment options, as well as surgery in well-selected patients requires careful consideration of predictive biomarkers and importantly, the optimal sequence in which therapies should be given to derive maximal benefit. A group of colorectal subspecialty medical oncologists from Australia, USA, The Netherlands and Germany met during ECCO 2015 in Vienna to review current practice. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/19214 | DOI: | 10.1586/14737140.2016.1170594 | Journal: | Expert review of anticancer therapy | PubMed URL: | 27010906 | Type: | Journal Article | Subjects: | Colorectal cancer Consensus RAS VEGF biological chemotherapy |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.